Cancer-Associated Mutations in the MDM2 Zinc Finger Domain Disrupt Ribosomal Protein Interaction and Attenuate MDM2-Induced p53 Degradation

REFERENCES

• Alam, S. L., J. Sun, M. Payne, B. D. Welch, B. K. Blake, D. R. Davis, H. H. Meyer, S. D. Emr, and W. I. Sundquist. 2004. Ubiquitin interactions of NZF zinc fingers. EMBO J. 23:1411–1421.
   PubMedGoogle Scholar
• Argentini, M., N. Barboule, and B. Wasylyk. 2001. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20:1267–1275.
   PubMed Web of Science ®Google Scholar
• Bartel, F., H. Taubert, and L. C. Harris. 2002. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2:9–15.
   PubMed Web of Science ®Google Scholar
• Bhat, K. P., K. Itahana, A. Jin, and Y. Zhang. 2004. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 23:2402–2412.
   PubMed Web of Science ®Google Scholar
• Boyd, S. D., K. Y. Tsai, and T. Jacks. 2000. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nat. Cell Biol. 2:563–568.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo, C., E. Latres, M. Drobnjak, M. R. Oliva, D. Pollack, J. M. Woodruff, V. Marechal, J. Chen, M. F. Brennan, and A. J. Levine. 1994. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:794–799.
   PubMed Web of Science ®Google Scholar
• Corvi, R., L. Savelyeva, L. Amler, R. Handgretinger, and M. Schwab. 1995. Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line. Eur. J. Cancer 31A:520–523.
   PubMedGoogle Scholar
• Dai, M. S., Y. Jin, J. R. Gallegos, and H. Lu. 2006. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia 8:630–644.
   PubMed Web of Science ®Google Scholar
• Dai, M. S., and H. Lu. 2004. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem. 279:44475–44482.
   PubMed Web of Science ®Google Scholar
• Dai, M. S., S. X. Zeng, Y. Jin, X.-X. Sun, L. David, and H. Lu. 2004. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol. 24:7654–7668.
   PubMed Web of Science ®Google Scholar
• El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, D. M. Lin, W. E. Mercer, K. W. V. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825.
   PubMed Web of Science ®Google Scholar
• Enomoto, T., M. S. Lindstrom, A. Jin, H. Ke, and Y. Zhang. 2006. Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J. Biol. Chem. 281:18463–18472.
   PubMed Web of Science ®Google Scholar
• Fakharzadeh, S. S., S. P. Trusko, and D. L. George. 1991. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10:1565–1569.
   PubMed Web of Science ®Google Scholar
• Fang, S., J. P. Jensen, R. L. Ludwig, K. H. Vousden, and A. M. Weissman. 2000. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275:8945–8951.
   PubMed Web of Science ®Google Scholar
• Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:7288–7293.
   PubMed Web of Science ®Google Scholar
• Geyer, R. K., Z. K. Yu, and C. G. Maki. 2000. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat. Cell Biol. 2:569–573.
   PubMed Web of Science ®Google Scholar
• Guddat, U., A. H. Bakken, and T. Pieler. 1990. Protein-mediated nuclear export of RNA: 5S rRNA containing small RNPs in Xenopus oocytes. Cell 60:619–628.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296–299.
   PubMed Web of Science ®Google Scholar
• Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27.
   PubMed Web of Science ®Google Scholar
• Honda, R., and H. Yasuda. 2000. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19:1473–1476.
   PubMed Web of Science ®Google Scholar
• Itahana, K., K. P. Bhat, A. Jin, Y. Itahana, D. Hawke, R. Kobayashi, and Y. Zhang. 2003. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12:1151–1164.
   PubMed Web of Science ®Google Scholar
• Itahana, Y., E. T. H. Yeh, and Y. Zhang. 2006. Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol. Cell. Biol. 26:4675–4689.
   PubMedGoogle Scholar
• Iwakuma, T., and G. Lozano. 2003. MDM2, an introduction. Mol. Cancer Res. 1:993–1000.
   PubMed Web of Science ®Google Scholar
• Jin, A., K. Itahana, K. O'Keefe, and Y. Zhang. 2004. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 24:7669–7680.
   PubMed Web of Science ®Google Scholar
• Joazeiro, C. A., and A. M. Weissman. 2000. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102:549–552.
   PubMed Web of Science ®Google Scholar
• Jones, S. N., A. R. Hancock, H. Vogel, L. A. Donehower, and A. Bradley. 1998. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 95:15608–15612.
   PubMed Web of Science ®Google Scholar
• Jones, S. N., A. E. Roe, L. A. Donehower, and A. Bradley. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206–208.
   PubMed Web of Science ®Google Scholar
• Kamijo, T., J. D. Weber, G. Zambetti, F. Zindy, M. Roussel, and C. J. Sherr. 1998. Functional and physical interaction of the ARF tumor suppressor with p53 and MDM2. Proc. Natl. Acad. Sci. USA 95:8292–8297.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299–303.
   PubMed Web of Science ®Google Scholar
• Li, M., C. L. Brooks, F. Wu-Baer, D. Chen, R. Baer, and W. Gu. 2003. Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science 302:1972–1975.
   PubMed Web of Science ®Google Scholar
• Lohrum, M. A., R. L. Ludwig, M. H. Kubbutat, M. Hanlon, and K. H. Vousden. 2003. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3:577–587.
   PubMed Web of Science ®Google Scholar
• Lu, M. L., F. Wikman, T. F. Orntoft, E. Charytonowicz, F. Rabbani, Z. Zhang, G. Dalbagni, K. S. Pohar, G. Yu, and C. Cordon-Cardo. 2002. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin. Cancer Res. 8:171–179.
   PubMed Web of Science ®Google Scholar
• Luna, R. M., D. S. Wagner, and G. Lozano. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203–206.
   PubMedGoogle Scholar
• Ma, J., J. D. Martin, H. Zhang, K. R. Auger, T. F. Ho, R. B. Kirkpatrick, M. H. Grooms, K. O. Johanson, P. J. Tummino, R. A. Copeland, and Z. Lai. 2006. A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45:9238–9245.
   PubMed Web of Science ®Google Scholar
• Marechal, V., B. Elenbaas, J. Piette, J.-C. Nicolas, and A. J. Levine. 1994. The ribosomal L5 protein is associated with mdm-2 and mdm2-p53 complexes. Mol. Cell. Biol. 14:7414–7420.
   PubMed Web of Science ®Google Scholar
• Martin, K., D. Trouche, C. Hagemeier, T. Sorensen, N. B. La Thangue, and T. Kouzarides. 1995. Stimulation of E2F/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375:691–694.
   PubMed Web of Science ®Google Scholar
• Meulmeester, E., R. Frenk, R. Stad, P. de Graaf, J.-C. Marine, K. H. Vousden, and A. G. Jochemsen. 2003. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol. Cell. Biol. 23:4929–4938.
   PubMed Web of Science ®Google Scholar
• Meyer, H. H., Y. Wang, and G. Warren. 2002. Direct binding of ubiquitin conjugates by the mammalian p97 adaptor complexes, p47 and Ufd1-Npl4. EMBO J. 21:5645–5652.
   PubMed Web of Science ®Google Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245.
   PubMed Web of Science ®Google Scholar
• O'Keefe, K., H. Li, and Y. Zhang. 2003. Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol. Cell. Biol. 23:6396–6405.
   PubMedGoogle Scholar
• Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362:857–860.
   PubMed Web of Science ®Google Scholar
• Pilotti, S., G. Della Torre, C. Lavarino, S. Di Palma, G. Sozzi, F. Minoletti, S. Rao, G. Pasquini, A. Azzarelli, F. Rilke, and M. A. Pierotti. 1997. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J. Pathol. 181:14–24.
   PubMed Web of Science ®Google Scholar
• Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, and R. A. DePinho. 1998. The INK4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713–723.
   PubMed Web of Science ®Google Scholar
• Reifenberger, G., L. Liu, K. Ichimura, E. E. Schmidt, and V. P. Collins. 1993. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:2736–2769.
   PubMed Web of Science ®Google Scholar
• Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:554–564.
   PubMed Web of Science ®Google Scholar
• Schlott, T., S. Reimer, A. Jahns, A. Ohlenbusch, I. Ruschenburg, H. Nagel, and M. Droese. 1997. Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumors. J. Pathol. 182:54–61.
   PubMed Web of Science ®Google Scholar
• Stommel, J. M., N. D. Marchenko, G. S. Jimenez, U. M. Moll, T. J. Hope, and G. M. Wahl. 1999. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18:1660–1672.
   PubMed Web of Science ®Google Scholar
• Stott, F. J., S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, and G. Peters. 1998. The alternative product from the human CDK2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001–5014.
   PubMed Web of Science ®Google Scholar
• Su, L., R. J. Hershberger, and I. L. Weissman. 1993. LYAR, a novel nucleolar protein with zinc finger DNA-binding motifs, is involved in cell growth regulation. Genes Dev. 7:735–748.
   PubMed Web of Science ®Google Scholar
• Tamborini, E., G. Della Torre, C. Lavarino, A. Azzarelli, P. Carpinelli, M. A. Pierotti, and S. Pilotti. 2001. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas. Int. J. Cancer 92:790–796.
   PubMed Web of Science ®Google Scholar
• Tanimura, S., S. Ohtsuka, K. Mitsui, K. Shirouzu, A. Yoshimura, and M. Ohtsubo. 1999. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett. 447:5–9.
   PubMed Web of Science ®Google Scholar
• Tao, W., and A. J. Levine. 1999. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 96:3077–3080.
   PubMed Web of Science ®Google Scholar
• Thut, C. J., J. A. Goodrich, and R. Tjian. 1997. Repression of p53-mediated transcription by MDM2, a dual mechanism. Genes Dev. 11:1974–1986.
   PubMedGoogle Scholar
• Wallace, M., E. Worrall, S. Pettersson, T. R. Hupp, and K. L. Ball. 2006. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol. Cell 23:251–263.
   PubMedGoogle Scholar
• Xiao, Z., J. Chen, A. J. Levine, N. Modjtahedi, J. Xing, W. R. Sellers, and D. M. Livingston. 1995. Interaction between the retinoblastima protein and the oncoprotein MDM2. Nature 375:694–698.
   PubMed Web of Science ®Google Scholar
• Xirodimas, D. P., C. W. Stephen, and D. P. Lane. 2001. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp. Cell Res. 270:66–77.
   PubMedGoogle Scholar
• Yu, G. W., M. D. Allen, A. Andreeva, A. R. Fersht, and M. Bycroft. 2006. Solution structure of the C4 zinc finger domain of HDM2. Protein Sci. 15:384–389.
   PubMedGoogle Scholar
• Zhang, Y., G. White Wolf, K. Bhat, A. Jin, T. Allio, W. A. Burkhart, and Y. Xiong. 2003. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol. 23:8902–8912.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., and Y. Xiong. 2001. A p53 amino terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 292:1910.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., and Y. Xiong. 2001. Control of p53 ubiquitination and nuclear export by MDM2 and ARF. Cell Growth Differ. 12:175.
   PubMedGoogle Scholar
• Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725–734.
   PubMed Web of Science ®Google Scholar